PROM1 and glioblastoma: Similarly to our findings, different clinical outcomes were documented in a study that divided GBM patients into 2 groups (CD133-low, CD133-high) according to CD133+ cell ratio either < 3% or ≥ 3%, as detected by the fluorescence activated cell scanning (FACS) analysis of primary tumour cultures.